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a  b  s  t  r  a  c  t
This study  aimed  to  investigate  potential  acute  and  subchronic  toxicity  of rhodium  (II) citrate  in female
Balb/c  mice  after  intraperitoneal  injections.  In  the acute  test,  independent  groups  received  ﬁve doses;
the  highest  dose  (107.5  mg/kg)  was  equivalent  to  33  times  that  used  in  our  previous  reports.  The  other
doses  were  chosen  as proportions  of the highest,  being  80.7  (75%),  53.8  (50%),  26.9  (25%)  or  13.8 mg/kg
(12.5%).  Animals  were  monitored  over  38 days  and no severe  signs  of  toxicity  were  observed,  according
to  mortality,  monitoring  of  adverse  symptoms,  hematological,  biochemical  and  genotoxic  parameters.
We  conclude  that  the  median  lethal  dose  (LD50) could  be greater  than  107.5  mg/kg.  In  the  subchronic
test,  ﬁve  doses  of Rh2Cit  (80,  60,  40,  20  or 10 mg/kg)  were  evaluated  and  injections  were  conductedenotoxicity
oxicological analysis
ethal dose
cute and subchronic toxicity
on alternate  days,  totaling  ﬁve  applications  per  animal.  Paclitaxel  (57.5  mg/kg)  and  saline  solution  were
controls.  Clinical  observations,  histopathology  of liver,  lung  and  kidneys  and  effects  on hematological,
biochemistry  and  genotoxic  records  indicated  that Rh2Cit induced  no  severe  toxic  effects,  even at  an
accumulated  dose  up to 400  mg/kg.We  suggest  Rh2Cit  has  great  potential  as an antitumor  drug  without
presenting  acute  and  subchronic  toxicity.
© 2015  Published  by  Elsevier  Ireland  Ltd.  This is an  open  access  article  under the CC  BY-NC-ND. Introduction
The use of metals or metal containing compounds in the thera-
eutics of cancer has been reported since the sixteenth century.
rom the 1960s onwards, with the discovery of cisplatin, many
esearchers have investigated the anticancer properties of a large
umber of other metal complexes. Platinum-based drugs have rev-
lutionized the treatment of testicular and ovarian solid tumors,
espite inducing high toxicity and cell chemoresistance [22,36].
nterestingly, rhodium carboxylates, a class of metal complexes,
ave presented promising antitumor activity in cisplatin-resistant
ell lines. These complexes showed cytostatic activity in tumors
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L1210, Ehrlich ascites carcinoma [2,51,40] sarcoma 180 and P388
and melanoma B16 [19,20]. However, further investigations have
discouraged researchers due to their toxicity in normal cells [17].
Recent structural studies suggest that the antitumor activity of
dirhodium (II) carboxylates may  occur by binding to adjacent gua-
nines in DNA, in a similar manner to cisplatin [22]. Others studies
indicated that the effect of rhodium (II) acetate, propionate and
methoxyacetate is to irreversibly inhibit all enzymes that have a
sulfhydryl group in or near their activity site [19,20].
Among the class of rhodium carboxylates, rhodium (II) citrate
(Rh2Cit) presented antitumor, cytotoxic, and cytostatic activity on
Ehrlich ascites carcinoma. Prominently, this complex has shown
itself to be a promising antitumor agent for chemotherapy since it
induces lower toxicity to normal cells when compared to analogous
rhodium carboxylates [50,51]. Rh2Cit structure is similar to that of
other rhodium (II) carboxylates, with dinuclear Rh (II) ions bound
by four bridging citrate ligands [9]. This complex has a molecular
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eight of 941.74 and solubility of 7 mg/mL  at room temperature
1]. Recently, our research group has demonstrated that Rh2Cit
nduced signiﬁcant cytotoxic effects on 4T1 and MCF-7 mammary
arcinoma cell lines [6,7], and it presented antitumor effect on
n orthotopic 4T1 carcinoma model after intratumoral and intra-
enous administration in Balb/c mice [6,7,37,38]. Although these
tudies have demonstrated the great potential of these complexes,
here are limited reports about their toxicity. In order to explore
he prospects for Rh2Cit in biomedical applications, we designed
he present study to assess its acute and subchronic toxicity pro-
les in mice and, thus, to obtain safety information regarding its
se as a therapeutic compound.
It is important that promising drugs be widely evaluated, in
articular to allow the development of procedures and practices,
hich can prevent further injury and/or disease as well as lead to
he introduction of more effective and safer therapies for patients
39]. Pre-clinical tests involving animal models are fundamental
o test a new therapeutic drug since they have been validated as
elatively accurate predictors of hazards to which humans may  be
xposed [41,23,42].
Adverse drug effects related to toxicity depend on many
arameters such as dose, route of administration and duration of
xposure. Acute toxicity, for instance, can be determined by the
ffects of a single exposure to a substance, and subchronic toxicity
valuation is useful to determine the presence of toxic effects after
epeated exposure and extended duration. On the other hand, it
s important to investigate the reactions of animals after repeated
dministrations because this approach can enhance the clinical efﬁ-
acy, but it can also cause toxicity and severe reactions [5,41]. Drug
oxicity often manifests in bone marrow, causing a range of serious
ide effects, including leucopenia (especially neutropenia), bone
arrow suppression (especially myelosupression) or immunotox-
city. Thus, the assessment of the potentially toxic impact of new
ompounds on bone marrow is important during drug discovery,
ince drug toxicity often manifests in this tissue [39].
Thereby, the choice of therapeutic strategy must consider clin-
cal signs of toxicity (such as pain or discomfort in animals),
ematological and biochemical information, pathological observa-
ions in tissues and organs and potential evaluation of genotoxicity.
hese toxicological evaluations may  predict potential adverse
ffects of a studied drug in humans [41] . In this context, the aim
f this study was to investigate the acute and subchronic toxicity
nduced by Rh2Cit in female Balb/c mice through its effects on the
ortality, clinical status, gross and microscopic pathology, hema-
ological and biochemical parameters and its genotoxic potential
n the bone marrow.
. Materials and methods
.1. Preparation of rhodium (II) citrate
Rhodium (II) citrate (Rh2Cit) was prepared and character-
zed as previously described. Brieﬂy, Rh2Cit was  synthesized by
xchanging triﬂuoroacetate ligands from the precursor rhodium (II)
riﬂuoroacetate with citrate ligands. The compound was  obtained
s a green aqueous solution with a standardized concentration of
.054 mol/L.
.2. Animals
Ninety female Balb/c mice (12 weeks old) were purchased from
he Multidisciplinary Center for Biological Investigation on Labo-
atory Animal Science (Cemib) of the State University of Campinas
Unicamp, SP/Brazil). Upon arrival, all animals were examined for
ealth condition to conﬁrm their suitability for study. All mice wereeports 2 (2015) 1086–1100 1087
housed in polycarbonate cages with ventilation under standard
conditions (temperature: 23 ± 3 ◦C; relative humidity: 50 ± 10%)
and 12 h dark/light cycle. After an acclimatization period of 20 days,
the animals, with ages of 12–16 weeks and a weight of 25.6 ± 2.02 g,
were randomly distributed in treatment groups (n = 6 or 8/per
group). The animals had free access to water and food.
All care and procedures were conducted according to the guide-
lines of the Animal Research Ethics Committee of the University
of Brasilia — Institute of Biological Sciences, Brazil (process no
109,434/2008).
2.3. Experimental design: treatment and conduct of animals in
acute and subchronic toxicity experiments
The antitumor effect of free Rh2Cit on mice bearing breast
cancer has been demonstrated in our previous articles by two
routes: intratumoral [6,7] and intravenous [37]. The best results
were obtained by the intratumoral route. In this present study, we
accessed the intraperitoneal route (i.p.) because it is the most simi-
lar route to on-site therapies (intramammary injection) in relation
to pharmacokinetic parameters, such as absorption, distribution
and elimination. Direct administration of cytotoxic drugs into the
peritoneal cavity is a strategy designed to enhance locoregional
drug delivery while abrogating systemic toxicities. Furthermore,
this route allows concentrations to be attained at the site of the
tumor that are many times higher than would be tolerated in the
systemic circulation; these can easily exceed concentrations shown
in vitro to be required to overcome clinical drug resistance. This
strategy has been developed and described in several Phase 1 clin-
ical trials, especially for ovarian tumors and peritoneal metastasis,
with wide extended action and reduced side effects.
3. Animal treatment
3.1. Acute toxicity
A total of 42 mice were assigned randomly to six groups of
eight animals each. The rhodium (II) citrate (Rh2Cit) solution was
injected via intraperitoneal route in mice in a single dose contain-
ing 107.5 mg/kg Rh2Cit or proportional doses of it as 80.7 (75%),
53.8 (50%), 26.9 (25%) or 13.8 (12.5%), while the control group was
exposed to saline solution (0.9% w/v).
3.2. Subchronic toxicity
A total of 42 mice were assigned randomly to seven groups of
six animals each. The mice were treated with 300 L of solution
containing different concentrations of Rh2Cit (80, 60, 40, and 20
or 10 mg/kg) or paclitaxel (57.8 mg/kg, equivalent to clinical dose
used in humans). The negative control group was  injected with the
same volume (300 L) of saline solution (0.9% w/v). The mice of
Rh2Cit or saline experimental groups received repeated doses via
intraperitoneal injections every two days, totalizing ﬁve injections,
and the total maximum accumulated dose of Rh2Cit was 400 mg/Kg.
The mice treated with paclitaxel received only two  injections dur-
ing all the experimental period (5th and 28th day), totalizing an
accumulated dose of 115.6 mg/kg.
3.3. Clinical sign observation
After the medication, clinical symptoms indicative of changes
in normality with respect to eyes, diarrhea, skin ulcers, abdom-
inal cramps, hyper/hypoactivity, lethargy, neurological behavior
(changes in motor activity) and/or deaths were recorded daily.
For the acute toxicity assay, the general behavior of mice and
signs of toxicity were observed continuously for two hours after






















































Histomorphometric parameters analyzed in mice for the assessment of eventual
toxicity of rhodium (II) citrate subchronic treatment.
Organ Parameters
Kidney Number of glomeruli
Area of the Bowman’s capsule
interspace (m2)
Liver Area of the central vein (m2)
Number of inﬁltrating
mononuclear cells088 M.L.B. Carneiro et al. / Toxico
njection. Further, the mice were monitored once a day up to 38
ays, when the animals were euthanized. The body weights and
ood consumption were monitored on the ﬁrst (day 0) and ﬁnal
xperimental day (day 38).
For the subchronic toxicity experiment, mice were closely mon-
tored every day for any behavioral changes, toxicity signs and
ethality rate from dosing (day 0) to the end of the experiment (day
4). Body weights and food consumption were recorded on the ﬁrst
ay of the study (day 0) prior to dosing and then 11, 25, 32 and 43
ays thereafter.
.4. Toxicity analysis
For the analysis of both acute and chronic toxicity induced by
h2Cit, at the end of the experiments (days 38 and 44, respectively),
he mice were anesthetized with ketamine (80 mg/kg) and xylazine
10 mg/kg) by the intraperitoneal route. Then, blood samples (1 mL)
ere collected by intracardiac puncture to carry out the hemogram
nd biochemical dosages of serum glutamic pyruvic transaminase
GPT, also known as alanine aminotransferase or ALT) and creati-
ine. Afterwards, animals were immediately euthanized by cervical
islocation, according to the American Veterinary Medical Associ-
tion (AVMA) guidelines. Subsequently, lungs, kidneys and liver
ere surgically collected and processed for the histological analy-
es, and bone marrow was removed for genotoxicity analyses (DNA
ragmentation and cell cycle).
.5. Hematological parameters
The blood samples, collected in microtubes containing EDTA,
ere analyzed using an auto-hematology analyzer (XZ 2100 Sys-
ex  equipment) for white blood cells (WBC), red blood cells (RBC),
emoglobin (HGB), hematocrit (HCT), mean corpuscular volume
MCV), mean corpuscular hemoglobin (MCH) and platelets (PLT)
nalysis.
.6. Serum biochemistry parameters
For the biochemical analyses, blood samples collected with-
ut EDTA were transferred to vacutainer tubes and centrifuged
t 3000 rpm for ﬁve minutes. Then, GPT and creatinine levels
ere determined in the automated chemistry analyzer ADVIA 2400
Siemens), using the appropriate ADVIA reagents, protocols and
ontrols.
.7. Bone marrow genotoxicity analysis
In order to evaluate genotoxicity potential induced by Rh2Cit,
one marrow cells (BM) were collected from femurs and resus-
ended in one milliliter of fetal bovine serum (FBS, Gibco). These
ells were used to perform DNA fragmentation and cell cycle anal-
ses by ﬂow cytometry, which is a rapid detection method of
NA damage and interference with cell mitosis caused by several
gents. In this experimental approach, ﬂuorochromes (e.g., pro-
idium iodide) interact with DNA molecules present in the cell in
 stoichiometric basis; i.e., DNA from cells in G2 phase (4n) will
ave proportionally more dye and will ﬂuoresce more brightly than
NA from G1 phase cells (2n) or fragmented DNA (<2n). Thus, the
roportion of cells in each cell cycle phase or the presence of frag-
ented DNA can be classiﬁed according to the ﬂuorescent bright
attern of the analyzed samples [10,11].
Brieﬂy, cells were ﬁxed in cold 70% ethanol, and stored overnight
t −30 ◦C. Afterwards, the cells were centrifuged and incubated
ith 300 L of lysis buffer (0.1% sodium citrate, 0.1% Triton X-100
nd 20 g/mL of propidium iodide, diluted in PBS pH 7.4) for 30 min
t room temperature and protected from light. DNA fragmentationLung Area of the alveolar air space (m2)
Thickness of the alveolar wall (m)
and cell cycle were analyzed using a FACSCalibur® ﬂow cytome-
try (Becton & Dickenson, USA) and a total of 10,000 events were
collected per sample.
3.8. Histopathological analysis
Firstly, liver, lung and kidneys were macroscopically examined
in respect to their color, consistency and size. Histopathology anal-
ysis of these organs was also performed in order to verify possible
toxic effects induced by treatments, to examine general aspects of
organ preservation, as well as evaluations of presence of inﬂam-
matory inﬁltrate (all organs), nuclear pyknosis (all organs), cell
desquamation (kidneys) and other histological pathologies. Thus,
tissues were ﬁxed in paraformaldehyde (4% at room temperature)
for 24 h, transferred to 70% ethanol and included in parafﬁn using
an automatic tissue processor (OMA® DM-40, São Paulo, Brazil).
Then, sections were cut to 5 m of thickness in a Leica RM2235
manual microtome (Leica Microsystems, Nussloch, Germany) and
stained with hematoxilin-eosin (HE) for histological analyses (light
microscopy). Sections were photographed with an MC 80 DX cam-
era coupled to a Zeiss Axiophot light microscope (Carl Zeiss).
In addition to the evaluated general aspects of parenchyma
integrity, and with the aim of making the examination more
objective, sensitive and accurate, some morphometric parameters
(Table 1) were measured by means of image analysis using the soft-
ware Image Pro-Plus 6.0 (Media Cybernetics, Silver Spring, USA).
Proper calibration of the digital tools was performed before each
analysis. Details of sampling are described along with the respective
results.
3.9. Statistical analysis
Statistical analysis was carried out using the SPSS (Statistical
Package for the Social Sciences) version 17.0 and Prism version 5.0
softwares. Data were expressed as mean ± SEM (standard error of
mean) and values of p < 0.05 were considered statistically signif-
icant. Quantitative variables were tested for normal distribution
with the Shapiro–Wilk test. Possible differences among groups
were investigated by performing ANOVA or the Kruskal–Wallis test
(data not normally distributed), followed respectively by Bonfer-
roni’s or Dunn’s multiple comparison tests. The Wilcoxon test (data
not normally distributed) was  used to verify differences between
initial and ﬁnal body weight inside each group. For the analyses
of body weight over time (subchronic toxicity), the Friedman Test
was used, followed by the Wilcoxon Test (2-to-2 comparisons).
4. Results
4.1. Clinical signs and mortalityIn Table 2, the ratio of animals with clinical signs and the mortal-
ity after the different treatments are shown. According to the acute
toxicity analysis, the animals that received Rh2Cit had no severe
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Table  2
The ratio of animals with clinical signs and the mortality after different treatments.
Treatment N animals Animals with clinical sign/treated animals Died animals/treated animals
Acute toxicity Negative control 8 0/8 0/8
Rh2Cit 107.57 mg/Kg 8 5/8 0/8
Rh2Cit 80.7 mg/Kg 8 6/8 0/8
Rh2Cit 53.8 mg/Kg 8 6/8 0/8
Rh2Cit 26.9 mg/Kg 8 0/8 0/8
Rh2Cit 13.8 mg/Kg 8 1/8 0/8
Subchronic toxicity Negative control 6 0/6 0/6
Rh2Cit 80 mg/Kg 6 0/6 0/6
Rh2Cit 60 mg/Kg 6 0/6 0/6
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igns of toxicity or mortality in any experimental group. This indi-
ates that the median lethal dose (LD50) of rhodium citrate is more
han 107.5 mg/kg. Although animals from the group treated with
he single dose of 107.5 mg/kg (the highest dose) presented clini-
al symptoms such as lethargy and mild abdominal cramps in the
rst two hours after the treatments, these reactions were transi-
ory. During this period, we observed, in the 80.7 mg/Kg Rh2Cit and
3.8 mg/Kg Rh2Cit groups, that the treatment caused hyperactiv-
ty in almost all the mice, and one animal in the 53.8 mg/Kg Rh2Cit
roup had hypoactivity. However, these clinical signs of toxicity
nd/or abnormalities in neurological function were not observed
hereafter until day 38 (end of the experimental period).
In the subchronic toxicity study, no clinical signs were seen of
ystemic toxicity such as diarrhea, ataxia, spasms, bleeding, vom-
ting, dyspnea, lethargy, hypoactivity, sweating and appearance
f spots or alopecia, or abnormalities in neurological functions
fter administration of Rh2Cit. However, in animals treated with
aclitaxel (57.8 mg/kg), hypoactivity was observed during the two
ubsequent hours after treatment; and, three days after the ﬁrst
njection of paclitaxel, hair loss was noticed until the end of the
xperiment.
.2. Body weight and food consumption
In relation to the acute toxicity study, we veriﬁed a signiﬁcant
ncrease in body weight of mice treated with saline (negative con-
rol) and 26.9 mg/kg Rh2Cit between the beginning (day 0) and the
nd of the experiment (day 38) (Fig. 1A). However, comparing the
ercentage of body weight gain or loss it was observed that all
roups had an average increase of about 5% (Supplementary data
). Food and water consumption was also not signiﬁcantly different
etween the control and Rh2Cit tested groups (data not shown).
In the subchronic toxicity test, an average increase was  observed
n the ﬁnal body weight (day 44) compared to the start of the exper-
ment (day 0), except for the 10 mg/kg Rh2Cit group, which had
 reduction in the ﬁnal body weight of mice (Fig. 1B). In general,
e observed an average gain in body weight of mice beneath 8%,
xcept in the 10 mg/kg Rh2Cit group, which showed an average
eduction of 11%, between day 0 and day 44 (Supplementary data
). However, this group, like the other treated groups, showed no
igniﬁcant differences compared to the negative control at the end
f the experiment (Fig. 1B).
.3. Hematological analysesAs compared to the negative control, although some signiﬁcant
ifferences have been observed in the erythrogram of the acute
nd subchronic toxicity assays, values were inside the reference
ntervals (Table 3).6 0/6
6 0/6
6 0/6
In respect to the leukogram of the acute toxicity tests, in the
group treated with 80.7 mg/kg Rh2Cit, there was  a signiﬁcant
decrease in the number of white blood cells (WBC) as compared
to the negative control (saline group), which was mainly related to
a reduction in lymphocytes, although inside the reference inter-
vals [14]. The treatment with 100.57 mg/kg Rh2Cit promoted a
signiﬁcant increase in the number of segmented neutrophils, while
that with 53.8 mg/kg Rh2Cit showed a reduction in the num-
ber of these cells, also inside the reference intervals for mice
[14].
In the analyses of subchronic toxicity, the only group in which
a signiﬁcant reduction of the WBC  occurred, also related to the
lymphocyte number, was  that treated with 60 mg/kg Rh2Cit. How-
ever, as in the acute toxicity, both WBC  and lymphocyte quantities
were inside the reference intervals for mice (Fig. 2) [14]. A signif-
icant increase was also observed in the number of monocytes in
the group treated with 10 mg/kg Rh2Cit. There were no signiﬁcant
changes in rods, basophils or eosinophils for the acute and sub-
chronic tests, the same occurring with the plateletgram (data not
showed).
4.4. Biochemical analyses
In the tests of acute toxicity, the only observed biochemical
alteration was related to an increase in serum glutamic pyruvic
transaminase (GPT) above the reference values [38] in the group
treated with 26.9 mg/kg Rh2Cit. For the subchronic toxicity tests,
the treatment with 20 mg/kg Rh2Cit was the only one that pro-
moted a signiﬁcant elevation in creatinine values, not affecting
GPT levels (Fig. 3). However, such increased creatinine levels were
still inside the reference values described for female Balb-C mice
[46].
4.5. Bone marrow genotoxicity analysis
In order to investigate whether an acute or subchronic expo-
sure to rhodium citrate (Rh2Cit) induces genotoxicity, bone marrow
cells of treated mice were collected and had their DNA evaluated
by ﬂow cytometry. The percentages of intact and fragmented DNA
of the experimental groups were similar to those found in the neg-
ative control group, indicating no signiﬁcant alterations in either
acute or subchronic exposures (Fig. 4).
Regarding differences between the treated groups, a signiﬁcant
increase was observed between the groups treated with 80 mg/kg
Rh2Cit or 10 mg/kg Rh2Cit in cell cycle proﬁle in the chronic toxicity
test.
In general, cell cycle proﬁle analysis of bone marrow cells
extracted from Rh2Cit treated mice showed no signiﬁcant alter-
ations when compared to the negative control group (Fig. 5).
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Fig. 1. Body weight of the Balb/c female mice in the acute (A) and subchronic (B) toxicity tests of rhodium citrate (Rh2Cit) administration evaluated for 38 and 44 days
respectively. Negative control received saline solution by intraperitoneal injection.
Data are presented as mean ± SEM (standard error of mean). The lowercase letters indicate signiﬁcant differences detected by Dunn’s multiple comparison test, with
a  = signiﬁcant compared to group 1; b = signiﬁcant compared to group 2; c = signiﬁcant compared to group 3; d = signiﬁcant compared to group 4; e = signiﬁcant compared to
group  5; f = signiﬁcant compared to group 5. Asterisks indicate signiﬁcant differences at *p < 0.05. The Wilcoxon test was used to verify differences among the initial and ﬁnal
body  weight inside each group ( /= ).
Table 3
Erythrogram of the Balb/c female mice in the acute and subchronic toxicity tests of rhodium citrate (Rh2Cit). Negative control received saline solution by intraperitoneal
injection.
Treatment Group RBC (x106/L) HGB (g/dL) HCT (%) MCV  (fL) MCH  (pg) MCHC (g/dL)
Acute toxicity Negative control 1 9.17 ± 0.17 14.78 ± 0.21 46.15 ± 0.45 50.37 ± 0.81 16.13 ± 0.24 32.05 ± 0.30
RhCit  107.57 mg/Kg 2 9.46 ± 0.12 14.52 ± 0.26 46.64 ± 0.84 49.32 ± 0.74 15.36 ± 0.28 31.10 ± 0.19
RhCit  80.7 mg/Kg 3 9.29 ± 0.07 14.46 ± 0.12 46.44 ± 0.30 49.96 ± 0.28 15.56 ± 0.07 31.12 ± 0.17
RhCit  53.8 mg/Kg 4 9.91 ± 0.10**a*c 15.50 ± 0.16*bc 47.90 ± 0.54 48.38 ± 0.06 15.65 ± 0.10 32.35 ± 0.21*bc
RhCit 26.9 mg/Kg 5 9.44 ± 0.13 14.56 ± 0.23*d 45.52 ± 0.78 48.20 ± 0.28 15.42 ± 0.09*a 32.00 ± 0.10
RhCit  13.8 mg/Kg 6 9.62 ± 0.07 14.84 ± 0.07 46.20 ± 0.38 48.02 ± 0.26 15.44 ± 0.10*a 32.14 ± 0.27
P-values 0.007 0.017 0.192 0.017 0.091 0.001
–
Subchronic toxicity Negative control 1 9.14 ± 0.2 14.80 ± 0.25 45.88 ± 0.44 50.26 ± 0.98 16.20 ± 0.29 32.26 ± 0.26
RhCit  80 mg/Kg 2 9.38 ± 0.11 14.63 ± 0.17 44.85 ± 0.62 47.85 ± 0.72 15.63 ± 0.20 32.63 ± 0.09
RhCit  60 mg/Kg 3 9.65 ± 0.17 14.86 ± 0.26 45.40 ± 0.70 47.10 ± 0.15**a 15.42 ± 0.10 32.76 ± 0.22
RhCit  40 mg/Kg 4 9.69 ± 0.11 15.04 ± 0.25 45.82 ± 0.61 47.28 ± 0.37**a 15.52 ± 0.13 32.80 ± 0.21*a
RhCit 20 mg/Kg 5 9.44 ± 0.40 14.27 ± 0.58 44.50 ± 1.48 47.20 ± 0.64*a 15.13 ± 0.09*a 32.03 ± 0.28
RhCit  10 mg/Kg 6 9.01 ± 0.20 13.77 ± 0.42*d 42.23 ± 1.29 46.90 ± 0.7*a 15.27 ± 0.24 32.60 ± 0.06
P-values 0.131 0.288 0.069 0.035 0.016 0.209
Data are presented as mean ± SEM (standard error of mean). RBC = Red Blood Cells; HGB = Hemoglobin; HCT = Hematocrit; MCV  = Mean Corpuscular volume; MCH  = Mean
Corpuscular hemoglobin; MCHC = Mean corpuscular hemoglobin concentration; g/dL = grams per deciliter; ﬂ = fentoliters; pg = picograms. For the acute toxicity, p-value of
MCH  was generated by the Kruskall–Wallis test, while p-values of the other parameters were generated by ANOVA; for the chronic toxicity, RBC, HCT and MCH  were generated
by  ANOVA, while p-values of the other parameters were generated by the Kruskall–Wallis test. The superscript letters indicate signiﬁcant differences detected by Bonferroni’s













rr  the Dunn’s multiple comparison tests, with a = signiﬁcant compared to group 1
ompared to group 4; e = signiﬁcant compared to group 5. Asterisks indicate signiﬁ
ell cycle proﬁle of mice submitted to a subchronic exposure of
0 mg/Kg Rh2Cit presented a proportion of cells that was  slightly
ifferent in the S and G2/M phases (10.5% and 17.2%, respectively),
howing that there was a tendency for the cell cycle to be arrested
Figs. 5D and F). Nevertheless, statistical analysis showed that this
ifference was not signiﬁcant. Only mice treated with 10 mg/Kg
h2Cit (group 6) had a signiﬁcantly different proportion of cells in
he S phase (17.8%), showing a discreet increase when compared
o group 2 (80 mg/Kg) after subchronic exposure (Fig. 5D). Over-
ll, these data indicate that acute or subchronic exposure to Rh2Cit
howed no biologically signiﬁcant alterations regarding bone mar-
ow cell cycle proﬁle.gniﬁcant compared to group 2; c = signiﬁcant compared to group 3; d = signiﬁcant
ifferences at *p < 0.05 and **p < 0.01.
4.6. Macroscopic and histopathological analyses of lung, liver and
kidneys
Evaluation of rhodium (II) citrate subchronic toxicity on the
parenchyma of kidney, liver and lung by means of histopathol-
ogy did not reveal any lesion or signiﬁcant alteration in these
organs. With respect to the renal cortex, tissue morphology of mice
treated with any of the dosages of rhodium (II) citrate was  pre-
served and similar to that of control animals (Fig. 6A and B). Normal
Malpighian corpuscles comprising a glomerulus enclosed within
a Bowman’s capsule were homogeneously distributed through-
out the parenchyma among many proximal and distal convoluted
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Fig. 2. Leukogram of the Balb/c female mice in the acute and subchronic toxicity tests of rhodium citrate (Rh2Cit). Negative control received saline solution by intraperitoneal
injection.
Data  are presented as mean ± SEM (standard error of mean). WBC  = White Blood Cells. The lowercase letters indicate signiﬁcant differences detected by Bonferroni’s (seg-
mented  neutrophils and monocytes) or Dunn’s (WBC and lymphocytes) multiple comparison tests, with a = signiﬁcant compared to group 1; b = signiﬁcant compared to
group  2; c = signiﬁcant compared to group 3; d = signiﬁcant compared to group 4; e = signiﬁcant compared to group 5. Asterisks indicate signiﬁcant differences at *p < 0.05
and  **p < 0.01.
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Fig. 3. Biochemical dosages of serum glutamic pyruvic transaminase (GPT) and creatinine in Balb/c female mice of the acute and subchronic toxicity tests of rhodium citrate
(Rh2Cit). Negative control received saline solution by intraperitoneal injection.






















aultiple comparison tests, with a = signiﬁcant compared to group 1; b = signiﬁcant
ifferences at *p < 0.05.
ubules (Fig. 6C and D), which often contained eosinophilic (pro-
einaceous) ﬁltrate. A reduction in the number of glomeruli counted
n 15 randomly analyzed visual ﬁelds (at 200 × magniﬁcation, for
ach of three studied animals per group) was noticed in some of the
reatment groups as compared to the control, especially in animals
hat received 20 mg/kg rhodium (II) citrate, which displayed the
owest numbers (Fig. 6E). Nevertheless, this decrease was  not sig-
iﬁcant (p < 0.05). On the other hand, an increase in the Bowman’s
apsule interspace area was detected in mice from some treatment
roups, but again differences were not signiﬁcant (Fig. 6F).
With regard to liver parenchyma, normal morphology of hepatic
obules and their components was observed in all the experimen-
al groups. Hepatocytes were radially arranged in cords around the
entral vein and displayed large, round and euchromatic nuclei
Fig. 7A). Some vacuolated hepatocytes were equally seen in sam-
les of all treatments, including the negative control (saline-treated
nimals). Well preserved portal tracts comprising a branch of the
epatic artery, a portal venule and a bile duct were found in all
he examined animals regardless of their groups (Fig. 7B). Inﬁltra-
ion of mononuclear cells was occasionally detected both in control
nd treated animals (Fig. 7C and D) with no signiﬁcant differencesared to group 2; c = signiﬁcant compared to group 3. Asterisks indicate signiﬁcant
(p < 0.05) in numbers among groups (Fig. 7E). The area of central
veins was  measured in 12 randomly analyzed microscopic ﬁelds
(at 200 × magniﬁcation) for each of the three studied animals per
group (the two images with the highest and lowest mean values
were discarded). Although an increase in the mean area of central
veins was  observed in some of the treatment groups as compared
to the control animals, especially in animals that received 20 mg/kg
rhodium (II) citrate or 57.80 mg/kg paclitaxel, this alteration was
not signiﬁcant (Fig. 7F).
Lung histopathology was  also performed to assess the effects
of rhodium on the alveoli, the functional portion of this organ.
Nevertheless, no alteration was  detected and samples of all the
experimental groups exhibited the same pattern of several alve-
olar air spaces separated by very thin alveolar septa (Fig. 8A–D).
The thickness of the alveolar walls was measured in 10 ran-
domly analyzed microscopic ﬁelds (at 200 × magniﬁcation) for
each of three studied animals per group (Fig. 8E), and no signiﬁ-
cant difference could be detected among all treatments (p > 0.05).
Similarly, the area of alveolar air spaces remained unchanged
after rhodium administration as compared to the control
(Fig. 8F).























big. 4. Evaluation of genotoxicity by DNA fragmentation analyses of bone marrow ce
itrate (Rh2Cit) in Balb/c female mice. Negative control received saline solution by i
ata are presented as mean ± SEM (standard error of mean).
. Discussion
Metal complexes have played an important role in increasing
he possibilities of chemotherapeutic compounds. However, the
mplementation of treatments is limited for safety reasons, includ-
ng the threat of severe adverse effects and intrinsic or acquired
esistance of tumor cells to the drugs [18]. Therefore, the search
or compounds of rhodium, which have lower toxicity and sig-
iﬁcant antitumor activity, has led researchers to synthesize and
est complexes with different carboxylate ligands, including citrate
30].
In cancer therapy, optimized dosing is crucial for establishing
ontoxic dose and safety for clinical use. Acute toxicity values such
s LD50 and adverse symptoms due to treatment are often used as
he basis for classifying chemicals into toxicity categories, and for
heir subsequent regulation [49,24,34,22].
In this respect, the compound Rh2Cit showed promising results
or cancer therapy, with LD50 superior to 107.5 mg/kg in a single
ose and superior to 400 mg/kg in accumulated doses, corroborat-
ng the literature [1]. The lethal dose to 50% of a population of mice
LD50) of citrate rhodium (II) has been estimated to be greater than
60 mg/kg [1]. However, no toxicity study of this compound has
een systematically reported.
Unlike Rh2Cit, other complexes of rhodium, such as acetate and
utyrate are highly toxic in mice, presenting values of DL10 ofder acute and subchronic exposure after intraperitoneal administration of rhodium
eritoneal injection.
0.7 mg/kg and 19 mg/kg, respectively [3]. Our study showed that
doses of up to than 107.5 mg/kg are clinically safe with no lethality,
suggesting that Rh2Cit may  be classiﬁed as a low-toxic substance
according to the toxicity categories of chemicals [35].
Nevertheless, studies on the effect of Rh2Cit treatment in accu-
mulated doses and over prolonged time have not been conducted.
Our study is the ﬁrst report about the subchronic toxicity of Rh2Cit.
We demonstrated that this complex did not produce any mortal-
ities or clinical signs of systemic toxicity in Balb/c mice after ﬁve
doses of up to 80 mg/kg/each (total dose of up to 400 mg/kg).
Severe intoxication symptoms and relevant changes in organ
appearance, histopathology, biochemical, hematological and geno-
toxicity parameters were not observed after accumulated dosing.
The observed clinical symptoms of lethargy and mild abdominal
cramps, in the ﬁrst two  hours after the treatments, were transitory
reactions. Andrade et al. [1] showed that 6 mg/kg Rh2Cit caused
an inﬂammatory response that was  characterized by a persistent
edema for 24 h when this complex was  injected into mice pads.
Moreover, these researchers found an increase in neutrophilic seg-
mented cells in the peritoneal exudate, as well as a signiﬁcant
increase in the number of spread monocytes when it was injected
in the peritoneal cavity of the mice. However, these effects could
probably be correlated to transitory reactions in response to drugs.
We found that the therapeutic dose (about 12 mg/kg, administered
in seven injections) used in our previous studies [6,7] is at least
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Fig. 5. Cell cycle proﬁle of bone marrow cells in acute and subchronic exposure after intraperitoneal administration of rhodium citrate (Rh2Cit) in Balb/c female mice.
Negative control received saline solution by intraperitoneal injection.
Data are presented as mean ± SEM (standard error of mean). The lowercase letter b indicates signiﬁcant difference compared to group 2 detected by the Bonferroni test.
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Fig. 6. Histological sections of renal cortex from Balb/C mice treated with rhodium (II) citrate at various concentrations. (A) Representative photomicrograph of kidney
parenchyma of animals from the negative control group; the large arrows indicate renal corpuscles. (B) Histological pattern of kidney cortex in mice treated with 20 mg/kg
rhodium (II) citrate; although no pathological alteration was noticed (as well as in the other treatments), a lesser number of glomeruli (large arrows) was  counted in 15
randomly analyzed microscopic ﬁelds (200x magniﬁcation) as compared to the control, but this reduction was  not signiﬁcant (E). (C) A renal corpuscle of a control animal is
shown in detail, with an intact glomerulus (thin arrow) enclosed within Bowman’s capsule; interspace areas (asterisk) were measured along with glomeruli count (F). (D)
Photomicrograph of proximal (p) and distal (d) convoluted tubules surrounding an intact renal corpuscle of an animal treated with 20 mg/kg rhodium (II) citrate, which is
representative of the histological pattern of all groups. Data are presented as mean ± SEM (standard error of mean).
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Fig. 7. Histological sections of liver from Balb/C mice treated with rhodium (II) citrate at various concentrations. Morphology remained unaltered after administration of
any  of the tested dosages. Therefore, unless otherwise stated, photomicrographs are representative of all experimental groups. (A) Central vein (cv) surrounded by cords of
hepatocytes radially arranged; the thin arrow indicates one of the sinusoids (s) opening into the central vein. (B) Portal area comprising branches of the portal vein (pv),
hepatic  artery (ha) and bile duct (bd). Vacuolation of hepatocytes (arrow head) was occasionally observed in a few lobules both in the negative control (C) and in all treatment
groups  (D) and was  associated to the presence of inﬁltrating mononuclear cells (large arrows), which were counted in 12 randomly analyzed microscopic ﬁelds. No signiﬁcant
differences in the numbers of these cells were detected among all groups (E). Similarly, central vein area was  not signiﬁcantly changed after any of the treatments as compared
to  the negative control (F). Data are presented as mean ± SEM (standard error of mean).
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Fig. 8. Histological sections of lung from Balb/C mice treated intraperitoneally with rhodium (II) citrate at various concentrations. Morphology remained unaltered after
administration of any of the dosages. (A) Alveoli of a control animal with a blood vessel (bv) containing several erythrocytes and some mononuclear cells; erythrocytes are










couse  treated with 80 mg/kg rhodium (II) citrate (B), which is representative of all
lveolar wall (septum) thickness were equally seen both in control and treated anim
s  mean ± SEM (standard error of mean).
3 times less than the highest dose used in this study (400 mg/kg,
dministered in ﬁve injections). Thus, we considered that Rh2Cit
ould be considered a low toxic drug.
Studies on genotoxicity risk assessment are among the param-
ters required by international regulatory agencies to guide the
afe use of pharmaceuticals [12]. Approaches and methods com-
rising DNA damage evaluations in bone marrow have often been
onducted for this purpose since it is a complex organ contain- rhodium treatments, and paclitaxel (C). Some areas with a slight reduction in the
). This parameter was assessed in 10 randomly analyzed mice. Data are presented
ing a variety of haematopoietic cells (including stem cells) that are
essential to give rise to nearly 10 different cell types present in the
peripheral blood [12,16]. It is known that cancer adjuvant therapies
using radiation, platinum compounds, antimetabolites, alkylating
agents, and anthracyclines induce unwanted side effects such as
myelotoxicity, leading to non- repaired DNA damage, alterations
in cell cycle, chromosomal instability, apoptosis, and mutations in
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one marrow cells collected from mice exposed to acute and sub-
hronic doses of Rh2Cit were submitted to DNA damage analysis to
valuate changes in the percentage of DNA integrity/fragmentation
nd cell cycle proﬁle.
Acute and subchronic treatments with different doses of Rh2Cit
id not induce signiﬁcant alterations in DNA fragmentation ratio of
one marrow cells. Considering that DNA fragmentation is a hall-
ark associated with cell death, particularly apoptosis [10,11], the
resent data suggest that Rh2Cit treatment did not affect bone mar-
ow cell viability. Precise and strict cell cycle regulation is required
or haematopoietic cells during normal blood cell development
31], whereas, disruptions in this regulation may  lead to failure
n blood production [16]. It has been reported that rhodium (II)
arboxylates, particularly sodium butyrate, inhibit DNA synthesis
n vivo and that cells in S phase are the ones mainly affected [2,3].
onversely, in the present work, the cell cycle proﬁle of bone mar-
ow cells did not show signiﬁcant alterations after Rh2Cit acute and
ubchronic treatments, suggesting that the Rh2Cit doses and treat-
ent regimens studied did not disturb the proliferation regulation
f these cells.
Myelosuppression is a common adverse effect of several
hemotherapy treatments, and it affects proliferation of bone
arrow cells, leading to temporary anemia, leucopenia, and
hrombocytopenia in peripheral blood [45,26]. Cisplatin-induced
yelosupression is considered mild and dose-dependent. Carbo-
latin induces a more severe myelosupression, when compared to
isplatin, showing intense incidence of neutropenia and thrombo-
ytopenia of 18 and 25%, respectively [13]. Paclitaxel is another
hemotherapeutic drug known to induce genotoxicity in bone mar-
ow cells [28] and was used in the present study as a positive
ontrol for DNA damage. Nevertheless, no signiﬁcant alterations
ere observed in DNA fragmentation or cell cycle proﬁle after
ubchronic exposure. Churin et al. [8] reported that paclitaxel
one marrow toxicity is evidenced a few days after administra-
ion, showing a reverse and recovered pattern 14 days later. Thus,
onsidering that genotoxicity and hematological parameters of
aclitaxel treated mice were evaluated on the 44th day, it is possi-
le that bone marrow features were reestablished to normal values.
ltogether, data obtained by DNA damage analysis of bone marrow
ells indicate that acute and subchronic treatments of Rh2Cit, in the
oses and treatment regimens studied, are non-myelosuppressive.
hese results are supported by blood analysis of treated mice show-
ng hematological parameter values within established reference
ntervals [14,38].
The kidney is one of the most commonly affected organs after
xposure to toxic compounds and such susceptibility can mainly
e attributed to its function. Concentrations of the ﬁltrate com-
onents are greatly increased across the tubular structure of each
ephron and reach very high levels (in some cases, there is a
100-fold rise) at distal tubules and collecting ducts [4]. There-
ore, since kidneys ﬁlter plasma continuously, toxic substances are
apidly and progressively accumulated at very elevated concentra-
ions in renal tissues, which make histopathological analysis of this
rgan a fundamental requirement in drug safety evaluation. In the
resent study, no alteration of the renal parenchyma morphology
as observed after any of the treatments with Rh2Cit as compared
o the negative control animals. This is another promising ﬁnding
hat favors the use of this compound in cancer therapy, since platin
erivatives are usually nephrotoxic.
Norrgren et al. [32] identiﬁed signs of tubular necrosis with
hronic inﬂammation, ﬁbrosis and missing tubuli in kidneys of Wis-
ar rats treated intraperitoneally with 5 mg/kg cisplatin (in three of
ve animals), whilst 5 mg/kg radioactive (191Pt) cisplatin seemed
o have a lower but still relevant toxicity in renal tissues, with one
20%) individual affected from a group of ﬁve rats. Similarly, Sherif
014 [43] observed, in Sprague–Dawley Rats injected intraperi-eports 2 (2015) 1086–1100
toneally with 7 mg/kg cisplatin, tubular damage characterized by
cellular degeneration and detachment, which was ameliorated, but
not avoided, by the use of Arjunolic acid, a compound extracted
from a plant in Indian medicine. In addition to the rigorous patho-
logical evaluation of the tissue samples in a blinded fashion, we
performed the assessment of morphometric parameters (number
of renal corpuscles per a deﬁned area and Bowman’s capsule area),
and signiﬁcant differences among treatments were still not present.
Thus, the increased creatinine levels in the group treated with
20 mg/Kg Rh2Cit may  be due to causes not related to the kidney
parenchyma rather than to a nephrotoxic effect of this dosage. A
rise in serum creatinine concentration can be caused by pre-renal,
renal and post-renal conditions. While pre-renal causes are related
to increased protein catabolism, renal causes are usually associated
with conditions that compromise 70–75% of functional renal mass,
and post-renal causes include any cause that results in the obstruc-
tion of the lower urinary system [15]. In addition, although no
evidence of renal lesions was  present, the analysis of nephrotoxic-
ity biomarkers such as the kidney injury molecule-1 (Kim-1), which
is a reliable marker for tubular epithelial injury prior to morpholog-
ical changes [44], may  contribute, in future studies, to assess early
adverse effects of our and other chemotherapeutic compounds on
renal parenchyma.
With respect to liver, histological patterns in mice treated with
any of the Rh2Cit dosages were similar to those found in ani-
mals that received only PBS. This organ is also very prone to
xenobiotic-induced injury because of its central role in xenobiotic
metabolism and its anatomic and physiologic structure [21]. There-
fore, this absence of effects corroborates the safety of anticancer
therapy with Rh2Cit. Conversely, intraperitoneal administration of
cisplatin at 10 mg/kg to Swiss mice led to hepatic tissue degener-
ation, with widespread apoptosis and vacuolization. Co-treatment
of these animals with extract of Boldo (Peumus boldus)  reduced, but
did not completely avoid, such hepatotoxicity of cisplatin [29]. In
the present study, along with a careful examination of liver sec-
tions with regard to tissue architecture and cell morphology and
counts of inﬁltrating mononuclear cells of what described above
(5–10 mg/kg groups), which exerted toxic effects in these sites.
On the other hand, the hypothesis of hormesis should not
be discarded; by which exposure to a low dose of a chemical
agent or environmental factor that is damaging at higher doses
induces an adaptive beneﬁcial effect on the cell or organism [28].
In other words, 26.9 mg/kg Rh2Cit (acute toxicity) and 20 mg/Kg
Rh2Cit (subchronic toxicity) doses increased the body’s tolerance
for greater toxicity, such as those of 107.57 and 80 mg/Kg Rh2Cit
dosage.
Lung parenchyma injury has often been associated with the use
of cisplatin in human subjects. Leo et al. [25] described the areas of
central veins and conﬁrmed that none of the treatments caused any
pathological alteration. Furthermore, it is noteworthy that even the
highest Rh2Cit dosage used in our investigation (80 mg/kg) did not
damage pivotal organs such as kidneys and liver, and is several-
fold higher than those of cisplatin in the studies described above
(5–10 mg/kg), which exerted toxic effects in these sites.
Moreover, Leo et al. [25] described the occurrence of pul-
monary tissue alterations such as foci of ﬁbroblastic proliferation
ﬁlling alveolar airspaces, diffuse alveolar damage with intersti-
tial/alveolar edema, presence of mild to moderate interstitial
ﬁbrous thickening, accumulation of macrophages and neutrophils
in the alveolar spaces and many other ﬁndings, in patients who
received preoperative chemotherapy with cisplatin. Therefore, we
also microscopically analyzed lung samples of treated animals with
the aim of determining whether Rh2Cit can also represent a safer
alternative to cisplatin with respect to pulmonary toxicity. Besides
the general histopathological evaluation, we also measured the
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lar wall in order to improve objectivity, accuracy and sensitivity
f the comparison between lung parenchyma from the control and
xperimental groups. No alteration could be noticed in the lungs of
ny of the Rh2Cit-treated animals, nor were any signiﬁcant differ-
nces among the morphometric parameters of all groups detected.
owever, for better understanding of these histopathological data,
ompound biodistribution studies will be performed later.
. Conclusion
In general, according to our acute and subchronic tests, in all
f the tested parameters, Rh2Cit- treated mice were similar to the
egative control, suggesting that this complex was nontoxic. Rh2Cit
id not induce mortality and its LD50 was superior to 400 mg/kg.
he intraperitoneal administration of Rh2Cit at the tested doses
nduced no relevant behavioral alterations, toxicological signs, or
ny other adverse effects on Balb/c mice during all experimental
eriods (38 and 44 days after dosing). Moreover, our study revealed
hat this complex does not have notable genetic toxicity. Thus, this
tudy provides evidence that indicates that Rh2Cit offers a good
otential as a novel antitumor drug for cancer treatment without
cute and subchronic toxic effects.
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